WEDNESDAY, Aug. 15, 2018 -- Single-agent talazoparib provides significant benefit over standard chemotherapy for patients with advanced breast cancer and germline BRCA1/2 mutation, according to a study published online Aug. 15 in the New England...
Original Article: Talazoparib Beneficial in Patients With Advanced Breast Cancer